Does reductive metabolism predict response to tirapazamine in lung cancer cells?
Author Information
Author(s): Chinje E C, Patterson A V, Saunders M P, Lockyer S D, Harris A L, Stratford I J
Primary Institution: Experimental Oncology Group, School of Pharmacy and Pharmaceutical Sciences, University of Manchester
Hypothesis
Does the enzyme NADPH:cytochrome P450 reductase influence the toxicity of tirapazamine in non-small-cell lung cancer cell lines?
Conclusion
The enzyme P450R significantly contributes to the activation of tirapazamine in lung cancer cells, affecting their sensitivity to the drug.
Supporting Evidence
- Tirapazamine selectively kills hypoxic tumor cells.
- P450R plays a significant role in the activation of tirapazamine.
- The study relates findings on lung cancer cells to previous research on breast cancer cells.
Takeaway
This study looked at how a specific enzyme helps a cancer drug work better in lung cancer cells.
Methodology
The study evaluated the role of NADPH:cytochrome P450 reductase in the metabolism and toxicity of tirapazamine across seven lung cancer cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website